Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
CERNCerner Corporation
0.93%70.597.6%$188.47m
LHLaboratory Corporation of America Holdings
0.36%166.832.3%$147.48m
DGXQuest Diagnostics Incorporated
0.41%98.044.3%$103.74m
SRCLStericycle, Inc.
-0.21%46.636.3%$57.40m
HCSGHealthcare Services Group, Inc.
0.43%32.596.7%$27.31m
OMCLOmnicell, Inc.
1.92%81.1010.5%$24.68m
MDRXAllscripts Healthcare Solutions, Inc.
1.49%10.1910.2%$17.25m
HMSYHMS Holdings Corp.
1.30%30.411.8%$16.25m
CPSIComputer Programs and Systems, Inc.
0.95%26.6232.6%$3.79m
HSTMHealthStream, Inc.
1.12%25.296.7%$2.39m
PMDPsychemedics Corporation
-1.41%10.510.7%$0.36m
IDXGInterpace Diagnostics Group, Inc.
0.66%0.733.3%$0.20m
PLXProtalix Biotherapeutics, Inc.
-1.94%0.395.8%$0.07m
BASIBioanalytical Systems, Inc.
0.00%2.000.3%$0.03m
STRMStreamline Health Solutions, Inc.
-0.73%1.360.3%$0.02m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.